Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, stem-cell company Osiris Therapeutics (Nasdaq: OSIR) has received the dreaded one-star ranking.

With that in mind, let's take a closer look at Osiris and see what CAPS investors are saying about the stock right now.

Osiris facts

Headquarters (Founded) Columbia, Md. (1992)
Market Cap $363.2 million
Industry Biotechnology
Trailing-12-Month Revenue $27.9 million
Management CEO Dr. Charles Mills (since 2004)
CFO Philip Jacoby Jr. (since 2009)
Return on Equity (Average, Past 3 Years) 12%
Cash/Debt $38.8 million / $0
Competitors Abbott Labs
Biogen Idec
UCB S.A.

Sources: S&P Capital IQ and Motley Fool CAPS.

On CAPS, 51% of the 73 All-Star members who have rated Osiris believe the stock will underperform the S&P 500 going forward.

Earlier this week, one of those Fools, All-Star BlacknGold, tapped Osiris as a particularly speculative selection:

Hopefully this speculative pharma red-thumb doesn't hurt me like some others have these past few months. I tend to agree with those who are realistic about the company's recent nod on Prochymal and ask "Yeah, so what?" This is tough for me because I am an absolute believer in the gargantuan impact stem cells will one day have on society. However, there are still too many obstacles and questions that remained to be answered.

If you want market-thumping returns, you need to protect your portfolio from any undue risk. Luckily, we've found another growth play we are incredibly excited about -- excited enough to dub it "The Only Stock You Need to Profit From the NEW Technology Revolution." We have compiled a special free report for investors to uncover this stock today. The report is 100% free, but it won't be here forever, so click here to access it now.

Want to see how well (or not so well) the stocks in this series are performing? Follow the TrackPoisedTo CAPS account.

Fool contributor Brian Pacampara owns no position in any of the companies mentioned. The Fool owns shares of Abbott Labs. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Fool's disclosure policy always gets a perfect score.